Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Comparing two targeted therapy drugs – is gefitinib safer than erlotinib?

Posted by on May 21, 2018 in Lung cancer | 0 comments

In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

Comparing gene-targeting therapy to standard chemotherapy in patients with early stage NSCLC

Posted by on Apr 9, 2018 in Lung cancer | 0 comments

In a nutshell This study compared gefitinib (Iressa) to cisplatin (Platinol)-based chemotherapy for treating patients with EGFR-mutation positive, early stage non-small-cell lung cancer, after surgery. The authors concluded that while treatment with gefitinib improved disease free survival compared to chemotherapy, they were unable to calculate overall...

Read More

The socioeconomic impact of cachexia in elderly patients with advanced lung cancer

Posted by on Apr 9, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the impact of cachexia (weakness or wasting of the body) in elderly patients with advanced non-small-cell lung cancer on disability, hospitalization and medical costs. The authors concluded that patients with cachexia had a higher risk of disability, longer hospital stays and higher medical costs, while being treated...

Read More

5 Things You Probably Didn’t Know About Your Adrenal Glands

5 Things You Probably Didn’t Know About Your Adrenal Glands

Posted by on Mar 15, 2018 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 3 comments

The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...

Read More

Right To Try: Needed Legislation or Snake Oil?

Right To Try: Needed Legislation or Snake Oil?

Posted by on Mar 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process.  There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...

Read More

Comparing the risk of specific side effects between chemotherapy regimens

Posted by on Mar 3, 2018 in Lung cancer | 0 comments

In a nutshell This study examined whether patients had a higher risk of thromboembolism depending on the chemotherapy drug they received. The study concluded that patients treated with carboplatin had no difference in the risk of thromboembolism compared to patients treating with cisplatin. Some background Chemotherapy is one of the most well-known...

Read More

Identifying patient factors that can predict the risk of local disease progression

Posted by on Mar 3, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at patients factors which would help predict local disease control for patients with inoperable non-small-cell lung cancer (NSCLC) who have been treated with chemoradiation therapy. The authors concluded that patients with squamous NSCLC, large tumor volume and first-line chemotherapy had a higher risk of worse local...

Read More

How effective is gefitinib at treating advanced non-small-cell lung cancer?

Posted by on Feb 17, 2018 in Lung cancer | 0 comments

In a nutshell This study summarized the effectiveness of gefitinib for treating advanced non-small-cell lung cancer. The authors concluded that gefitinib may be beneficial for prolonging time until progression and quality of life, particularly for patients with the specific genetic mutation EGFR. Some background Cancers can be caused by specific...

Read More